• Forest Laboratories Inc., of New York, and Pierre Fabre Medicament, of Castres, France, reported top-line results in a Phase III trial showing that levomilnacipran significantly reduced depression symptoms in patients with major depressive disorder compared to placebo, as early as week one and at each subsequent visit, as measured by the Montgomery-Asberg Depression Rating Scale-Clinician Rated.